Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation

Journal of Thoracic Disease

Volumn 7, Issue 3, 2015, Pages 346-355

  Ahmed, Inaya ^a   Ferro, Adam ^a   Cohler, Alan ^a   Langenfeld, John ^b   Surakanti, Sujani G ^a   Aisner, Joseph ^a   Zou, Wei ^a   Haffty, Bruce G ^a   Jabbour, Salma K ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Chemoradiation; Diabetes; Metformin; Non small cell lung cancer (NSCLC); Radiation therapy (RT); Radiosensitizer

Indexed keywords

ANTIDIABETIC AGENT; CARBOPLATIN; INSULIN; METFORMIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; ETHNICITY; FEMALE; HISTOLOGY; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84928621827     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2014.12.32     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
3. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available online: http://globocan.iarc.fr, accessed on 01/03/2014.
4. American Cancer Society. Cancer Facts & Figures 2014 [database online]. Atlanta: American Cancer Society, 2014.
5. Halperin EC, Perez CA, Brady LW. eds. Perez and Brady's Principles and Practice of Radiation Oncology. 5th Edition. Lippincott Williams & Wilkins, 2008.
6. Reck M, Heigener DF, Mok T, et al. Management of non-small-cell lung cancer: recent developments. Lancet 2013;382:709-19.
7. Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7:e33411.
8. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754-64.
9. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451-61.
10. Skinner HD, McCurdy MR, Echeverria AE, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013;52:1002-9.
11. Skinner HD, Crane CH, Garrett CR, et al. Metformin use and improved response to therapy in rectal cancer. Cancer Med 2013 Feb;2:99-107.
12. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302.
13. Sandulache VC, Hamblin JS, Skinner HD, et al. Metformin use is associated with improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 2014;36:1039-43.
14. Spratt D, Zhang C, Zumsteg ZS, et al. Metformin improves prostate cancer-specific survival and inhibits the development of castrate resistant metastasis. Int J Radiat Oncol Biol Phys 2012;84:S93.
15. Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012;119:61-7.
16. Kaushik D, Karnes RJ, Eisenberg MS, et al. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2014;32:43.e1-7.
17. Tan BX, Yao WX, Ge J, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011;117:5103-11.
18. Hwang AL, Haynes K, Hwang WT, et al. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas 2013;42:1054-9.
19. Cossor FI, Adams-Campbell LL, Chlebowski RT, et al. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol 2013;37:742-9.
20. Patel T, Hruby G, Badani K, et al. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010;76:1240-4.
21. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
22. Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12.
23. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110:246-50.
24. Storozhuk Y, Hopmans SN, Sanli T, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 2013;108:2021-32.
25. Algire C, Zakikhani M, Blouin MJ, et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008;15:833-9.
26. Jabbour SK, Daroui P, Moore D, et al. A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis 2011;3:4-9.
27. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011;8:378-82.
28. Ashworth A, Rodrigues G, Boldt G, et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 2013;82:197-203.
29. Griffioen GH, Toguri D, Dahele M, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer 2013;82:95-102.
30. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2010:253-70.
31. Gahagan S. Overweight and obesity. In: Kliegman RM, Behrman RE, Jenson HB, et al. eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Saunders Elsevier, 2011:chap 44.
32. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9.
33. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52.
34. Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol 2011;2011:583929.
35. Hatlen P, Grønberg BH, Langhammer A, et al. Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol 2011;6:1810-7.